Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Teva Pharmaceutical Industries Limited (TEVA.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
3,276.00-4.00 (-0.12%)
At close: 5:24PM IDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3,280.00
Open3,287.00
Bid4,401.00 x 200
Ask2,132.00 x 34100
Day's Range3,260.00 - 3,294.00
52 Week Range2,738.00 - 4,390.00
Volume1,054,912
Avg. Volume1,490,457
Market Cap3.611T
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-3.57
Earnings DateOct 27, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 28, 2017
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TEVA.TA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021

      TEL AVIV, Israel & PARSIPPANY, N.J., October 21, 2021--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 25 presentations examining new Phase 3 clinical data, post hoc analyses and open-label extension (OLE) studies for both TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) and AUSTEDO® (deutetrabenazine) tablets. Study findings will be presented at the upcoming 2021 Psych Congress Annual

    • Oilprice.com

      The Most Exciting Medical Breakthrough Of The Decade?

      Artificial intelligence is coming for the $11 trillion doctor industry, and it could change how you and your doctor interact for decades to come

    • Business Wire

      New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

      AMSTERDAM, October 13, 2021--Teva Pharmaceuticals Europe BV, a European affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital – Katholisches Klinikum Bochum (Bochum, Germany), presented today at ECTRIMS congress new analyses of the COBRA study, a real-world evidence study on the safety of COPAXONE® (glatiramer acetate or GA) used by mothers with multiple sclerosis (MS) during pregnancy and breastfeeding.

    Advertisement
    Advertisement